2-氨基-5,6-二氯-3,4-二氢喹唑啉氢溴酸盐 | 327602-34-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 2-氨基-5,6-二氯-3,4-二氢喹唑啉氢溴酸盐
• 英文名称: 2-amino-5,6-dichloro-3,4-dihydroquinazoline hydrogen bromide
• 英文别名: 2-amino-5,6-dichloro-3,4-dihydroquinazoline hydrobromide；5,6-dichloro-1,4-dihydroquinazolin-2-amine;hydrobromide
• CAS: 327602-34-6
• 化学式: BrH*C₈H₇Cl₂N₃
• 分子量: 296.982
• InChiKey: SZFQKLLDGWIZJF-UHFFFAOYSA-N

物化性质

• 熔点：
  >194°C (dec.)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.81
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  50.4
• 氢给体数：
  3
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-氨基-5,6-二氯-3,4-二氢喹唑啉氢溴酸盐 在 sodium hydride 作用下， 以 四氢呋喃 、 水 、 mineral oil 为溶剂， 反应 61.5h， 生成 5,6-dichloro-2-(2,3-dihydroxypropionylamino)-3,4-dihydroquinazolinium trifluoroacetate
  参考文献：
  名称：

  SYNTHESIS AND STABILITY OF 3-HYDROXYANAGRELIDE, A BIOLOGICALLY POTENT METABOLITE OF ANAGRELIDE

  摘要：

  Metabolism of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2-one (anagrelide), a drug for treating essential thrombocythemia, gives 6,7-dichloro-3-hydroxy-1,5-dihydroimidazo[2,1-b]quinazolin-2-one (3-hydroxyanagrelide) and 2-amino-5,6-dichloro-3,4-dihydroquinazoline. To enable the properties of 3-hydroxyanagrelide to be fully evaluated, the racemic compound has been synthesized. In pH 7.4 aqueous buffer 3-hydroxyanagrelide readily equilibrates with an isomer, 6,7-dichloro-1-hydroxy-3,5-dihydroimidazo[1,2-alpha]-quinazolin-2-one,and is also hydrolyzed to 2-amino-5,6-dichloro-3,4-dihydroquinazoline. 3-Hydroxyanagrelide (half-life 40 hours) was the dominant species at equilibrium and it was concluded that the equilibration and decomposition are sufficiently slow that published assays of 3-hydroxyanagrelide are reliable.

  DOI：

  10.3987/com-12-s(n)115
• 作为产物：
  描述：

  2,3-二氯苯甲醛 在 硝酸 作用下， 以 硫酸 、 水 为溶剂， 以50%的产率得到2-氨基-5,6-二氯-3,4-二氢喹唑啉氢溴酸盐
  参考文献：
  名称：

  2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof

  摘要：

  已发现，化合物2-氨基-5,6-二氯-3,4-二氢喹啉具有增强的降低血小板计数的特性。还提供了一种合成该化合物的方法，以及通过向患者投予该化合物的降低血小板计数的有效量的方法，最好与药学上可接受的载体一起。还提供了一种药物组合物，其中包含上述化合物作为活性成分，以及药学上可接受的辅料。

  公开号：

  US06194420B1

文献信息

• 2-AMINO-5,6-DIHALO-3,4-DIHYDROQUINAZOLINES WITH BLOOD PLATELET REDUCING PROPERTIES
  申请人：——

  公开号：US20030114673A1

  公开（公告）日：2003-06-19

  Compounds of formula (E) (wherein X and Y, which may be the same or different, each represents Cl, Br or F) and tautomers thereof have been found to have enhanced platelet count reducing properties. Also provided are methods for synthetically making the compounds of formula (E) and pharmaceutically acceptable addition salts thereof and a method of reducing the platelet count in patient by administering to the patient a platelet reducing effective amount of a compound of formula (E) preferably together with a pharmaceutically acceptable carrier. A pharmaceutical composition is also provided which contains a compound of formula (E) as the active ingredient together with pharmaceutically acceptable excipients. Further provided is a compound of formula (E) for use in therapy and the use of a compound of formula (E) for preparing a medicament for reducing platelet count in a patient.

  化学式为（E）的化合物（其中X和Y，可以相同或不同，分别代表Cl、Br或F）及其互变异构体已被发现具有增强的减少血小板计数的性质。同时提供了合成化学式（E）的化合物及其药学上可接受的盐的方法，以及通过向患者注射化学式（E）的化合物的减少血小板计数的方法，最好与药学上可接受的载体一起使用。还提供了一种含有化学式（E）的化合物作为活性成分的药物组合物，以及药学上可接受的辅料。此外，还提供了一种用于治疗的化学式（E）的化合物，以及用于制备减少患者血小板计数的药物的化学式（E）的化合物的用途。
• US6194420B1
  申请人：——

  公开号：US6194420B1

  公开（公告）日：2001-02-27
• 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof
  申请人：Roberts Laboratories Inc.

  公开号：US06194420B1

  公开（公告）日：2001-02-27

  The compound 2-amino-5,6-dichloro-3,4-dihydroquinazoline has been found to have enhanced platelet count reducing properties. Also provided are methods for synthetically making the compound and a method of reducing the platelet count in a patient by administering to the patient a platelet reducing effective amount of the compound preferably together with a pharmaceutically acceptable carrier. A pharmaceutical composition is also provided which contains the above compound as the active ingredient together with pharmaceutically acceptable excipients.

  已发现，化合物2-氨基-5,6-二氯-3,4-二氢喹啉具有增强的降低血小板计数的特性。还提供了一种合成该化合物的方法，以及通过向患者投予该化合物的降低血小板计数的有效量的方法，最好与药学上可接受的载体一起。还提供了一种药物组合物，其中包含上述化合物作为活性成分，以及药学上可接受的辅料。
• SYNTHESIS AND STABILITY OF 3-HYDROXYANAGRELIDE, A BIOLOGICALLY POTENT METABOLITE OF ANAGRELIDE
  作者：Bernard T. Golding、Richard B. Scott、Kristin M. Downey、Keith P. Healy、Alistair P. Henderson、Claire L. Robinson、William Clegg、Ross W. Harrington、Richard Franklin

  DOI：10.3987/com-12-s(n)115

  日期：——

  Metabolism of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2-one (anagrelide), a drug for treating essential thrombocythemia, gives 6,7-dichloro-3-hydroxy-1,5-dihydroimidazo[2,1-b]quinazolin-2-one (3-hydroxyanagrelide) and 2-amino-5,6-dichloro-3,4-dihydroquinazoline. To enable the properties of 3-hydroxyanagrelide to be fully evaluated, the racemic compound has been synthesized. In pH 7.4 aqueous buffer 3-hydroxyanagrelide readily equilibrates with an isomer, 6,7-dichloro-1-hydroxy-3,5-dihydroimidazo[1,2-alpha]-quinazolin-2-one,and is also hydrolyzed to 2-amino-5,6-dichloro-3,4-dihydroquinazoline. 3-Hydroxyanagrelide (half-life 40 hours) was the dominant species at equilibrium and it was concluded that the equilibration and decomposition are sufficiently slow that published assays of 3-hydroxyanagrelide are reliable.